Skip to Content

New Drug Approvals Archive - March 2018

See also: New Indications and Dosage Forms for March 2018

March 2018

Trogarzo (ibalizumab-uiyk) Injection

Date of Approval: March 6, 2018
Company: TaiMed Biologics USA Corp.
Treatment for: HIV Infection

Trogarzo (ibalizumab-uiyk) is a CD4-directed post-attachment HIV-1 inhibitor for the treatment of multidrug resistant human immunodeficiency virus-1 (HIV-1) infection in heavily treatment-experienced adults.

Ilumya (tildrakizumab-asmn) Injection

Date of Approval: March 20, 2018
Company: Sun Pharmaceutical Industries Ltd.
Treatment for: Plaque Psoriasis

Ilumya (tildrakizumab-asmn) is a humanized, anti-IL-23p19 monoclonal antibody for the treatment of moderate-to-severe plaque psoriasis.

Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate) Tablets

Date of Approval: March 22, 2018
Company: Mylan N.V.
Treatment for: HIV Infection

Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate) is a three-drug combination of a non-nucleoside reverse transcriptase inhibitor (efavirenz), and two nucleo(t)side reverse transcriptase inhibitors (lamivudine and tenofovir disoproxil fumarate) indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.

New Drug Approvals Archive

More News Resources

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.